Multiple Myeloma Biomarker Detection Service
The study of biomarkers has brought great changes to the treatment of multiple myeloma (MM) and the monitoring of disease course. As an expert in the field of biomarkers, Creative BioMart Biomarker has the ability to provide customers with high-quality single biomarker testing services, including biomarkers related to MM. We have a variety of technical platforms that can be used to provide detection services for various types of samples to meet the needs of different customers.
Multiple Myeloma and Biomarkers
MM is a common hematological malignant tumor after non-Hodgkin's lymphoma, accounting for 13% of all hematological tumors and 1% of tumor diseases. The clinical features of MM include uncontrolled proliferation and accumulation of abnormal bone marrow plasma cells, excessive production of immunoglobulins or light chains, and end organ damage, such as renal insufficiency, hypercalcemia, and anemia. MM involves multiple organs and is a combination of multiple diseases with a common clinical phenotype. Due to the lack of effective early diagnosis, MM has a high morbidity and mortality, in addition, most patients with MM will relapse. Although immunosuppressive agents and proteasome inhibitors are used in the treatment of MM, there are still many high-risk MM patients with short progression-free survival and low overall survival. As an indicator that can reflect the physiological state, disease state and pharmacological response of the human body, biomarkers bring a new research direction for the diagnosis and prognosis of MM. Due to the specificity, sensitivity and accuracy of biomarkers, they are mostly used for disease progression monitoring, prognosis analysis, disease stage and disease risk analysis. For example, based on the level of β2 microglobulin and albumin in serum, biomarkers can be used to assess the prognosis of MM. The International Staging System (ISS) is a method to assess the prognosis of MM based on this, which can divide the newly diagnosed patients into three stages. Although there are some biomarkers related to MM, it is necessary to develop more effective biomarkers that can be utilized in the early diagnosis, disease progression prediction and treatment response monitoring of MM.
Our Advantages
- Guarantee high accuracy and sensitivity for single biomarker detection
- Ensure high repeatability of single biomarker detection
- Short turn-around time of detection service
- Competitive price in the market of detection services
- Provide multiple detection methods
- Accept a wide range of sample types
Our Single Biomarker Detection Services Related to Multiple Myeloma (including but not limited to the following):
- BCMA Detection Service
- CTX-1 Detection Service
- P1NP Detection Service
- NTX Detection Service
- ICTP Detection Service
- RANKL Detection Service
- β2M Detection Service
- IL-6 Detection Service
- Syndecan-1 Detection Service
- Sclerostin Detection Service
- DKK1 Detection Service
- BCL-2 Detection Service
- Albumin Detection Service
Workflow of Single Biomarker Detection at Creative BioMart Biomarker
Creative BioMart Biomarker provides high-quality detection services for multiple myeloma biomarkers that are applicable to a variety of biomarkers. If you do not find detection services for your research object on this webpage, you can find more biomarkers in biomarker menu or contact us to get more help. We have a technical team with rich experience in tumor biomarker detection, as well as multiple technical platforms suitable for biomarker detection, capable of accurate, specific and sensitive detection for various types of samples. If you are seeking multiple myeloma biomarker detection services, please feel free to contact us, we look forward to being your trusted partner.
Reference:
- Huang, P. L. A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms. 2009, 2(5-6): 231-237.
